[Combination of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer].
The platinum-based combined chemotherapy is effective for advanced non-small cell lung cancer (NSCLC). This study is to observe the clinical effect and toxicity of combination of gemcitabine with cisplatin for advanced NSCLC. All of 32 patients were pathologically confirmed as stage III or IV NSCLC who lost chance to receive operation. Gemcitabine was given on days 1, 8, 15 at a dose of 1000mg/m² and cisplatin on days 1-5 at a dose of 20mg. The chemotherapy was repeated every 28 days up to 3-4 cycles. There was no patient who got complete response, and the overall response rate was 34.4% (11/32). The median survival duration was 329 days and the 1-year survival rate was 32.7%. The main toxicities were myelosuppression, nausea and vomiting, however, there was no severe grade IV damage or obvious liver and kidney damage. No one was delayed for chemotherapy due to adverse effect. The combination of gemcitabine and cisplatin is effective and well tolerated in the treatment of advanced NSCLC.